S. Rothschild

1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial

C. Britschgi, D. Betticher, M. Joerger, 2020 .

TCR-beta repertoire convergence and evenness are associated with response to immune checkpoint inhibitors

L. Bubendorf, P. Jermann, S. Savic Prince, 2019, Annals of Oncology.

Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.

R. Pillai, P. Leger, L. Horn, 2017 .

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

R. Stupp, A. Addeo, D. Betticher, 2022, ESMO open.

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14

R. Stupp, A. Addeo, D. Betticher, 2023, ESMO open.

Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies.

M. Joerger, A. Curioni-Fontecedro, C. Appenzeller, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

91PD_PRResponse to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC

R. Pillai, P. Leger, L. Horn, 2017 .